【摘要】 目的探讨齐拉西酮治疗奥氮平致体重增加精神分裂症患者的效果和安全性。方法选取2016年1月～2018年1月我院收治的84例精神分裂症患者作为研究对象,采用随机数字表法将其分为试验组和参照组,每组各42例。参照组患者采用奥氮平治疗,试验组患者给予齐拉西酮联合奥氮平治疗。治疗8周后,采用阳性和阴性症状量表(PANSS)和精神科不良反应量表(UKU)评估两组患者的治疗效果和不良反应,并观察两组患者治疗前后的体重、体重指数(BMI)、空腹血糖(GLU)、三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)。结果两组患者治疗前的PANSS评分比较,差异无统计学意义(P>0.05);两组患者治疗后的PANSS评分均明显低于治疗前,差异有统计学意义(P<0.05);两组患者治疗后的PANSS评分比较,差异无统计学意义(P>0.05)。两组患者治疗前的体重、BMI、GLU、TG、TC、HDL、LDL比较,差异无统计学意义(P>0.05);参照组患者治疗后的体重、BMI、GLU、TG、TC、HDL、LDL均高于治疗前,差异有统计学意义(P<0.05);试验组患者治疗前后的体重、BMI、GLU、TG、TC、HDL、LDL比较,差异无统计学意义(P>0.05);试验组患者治疗后的体重、BMI、GLU、TG、TC、LDL均低于参照组,差异有统计学意义(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论齐拉西酮能改善奥氮平治疗精神分裂症引起的糖脂代谢紊乱状态,从而有效防止体重增加,且安全性较高,值得临床推广和应用。更多还原

【Abstract】 Objective To investigate the effect and safety of Ziprasidone in the treatment of Olanzapine-induced body weight gain in patients with schizophrenia. Methods From January 2016 to January 2018, a total of 84 schizophrenic patients admitted to our hospital were selected as study subjects. They were divided into experimental group and reference group according to random number table method, with 42 cases in each group. The reference group was treated with Olanzapine and the experimental group was treated with Ziprasidone combined with Olanzapine. After 8 weeks of treatment, positive and negative symptom scale(PANSS) and psychiatric adverse reaction scale(UKU) were used to evaluate the therapeutic effect and adverse reactions of the two groups. And body weight, body mass index(BMI), fasting blood glucose(GLU), triglyceride(TG), total cholesterol(TC), high density lipoprotein(HDL), and low density lipoprotein(LDL) were observed before and after treatment. Results There were no significant differences in PANSS scores between the two groups before treatment(P>0.05). The PANSS scores after treatment in the two groups were significantly lower than those before treatment, and the differences were statistically significant(P<0.05). There were no significant differences in PANSS scores between the two groups after treatment(P>0.05). There were no significant differences in body weight, BMI, GLU, TG, TC, HDL and LDL between the two groups before treatment(P>0.05). The body weight,BMI, GLU, TG, TC, HDL and LDL after treatment in the reference group were higher than those before treatment, and the differences were statistically significant(P<0.05). There were no significant differences in body weight, BMI, GLU,TG, TC, HDL and LDL before and after treatment in the experimental group(P>0.05). The weight, BMI, GLU, TG, TC and LDL after treatment in the experimental group were lower than those in the reference group, and the differences were statistically significant(P<0.05). There was no significant difference in the total incidence rate of adverse reactions between the two groups(P>0.05). Conclusion Ziprasidone can improve the disorder of glycolipid metabolism induced by Olanzapine, thus effectively prevent the increase of body weight, and the safety is relatively high, which is worthy of clinical promotion and application.更多还原